PharmaCyte Biotech, Inc. (PMCB)
| Market Cap | 5.53M -16.2% |
| Revenue (ttm) | n/a |
| Net Income | -23.21M |
| EPS | -2.77 |
| Shares Out | 10.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,340 |
| Open | 0.5326 |
| Previous Close | 0.5402 |
| Day's Range | 0.5044 - 0.5326 |
| 52-Week Range | 0.5043 - 1.5100 |
| Beta | 0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 14, 2026 |
About PMCB
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company’s cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements w... [Read more]
Financial Performance
Financial StatementsNews
PharmaCyte sells Femasys stake, sees cash position rising to $20M
PharmaCyte Biotech (PMCB) announced the successful monetization of its stake in Femasys (FEMY). Following the monetization of the stake, PharmaCyte’s cash and marketable securities are expected to inc...
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further val...
PharmaCyte Biotech increases stake in TNF Pharmaceuticals by $3M
PharmaCyte Biotech (PMCB) announced that it has increased its stake in TNF Pharmaceuticals (TNFA) by an additional $3M. The company does so to help support TNF’s recent acquisition of a…
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, “TNF”) by an a...
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, ...
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million financing...
MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech
MyMD Pharmaceuticals (MYMD) announced that it has secured $7M in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech (PMCB), a clinical-stage biotechnol...
MyMD Pharmaceuticals Secures Strategic Investments
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-r...
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clin...
PharmaCyte Biotech makes $5M investment in Femasys to utilize cash position
PharmaCyte Biotech (PMCB) announces it has made a $5M investment in Femasys (FEMY) …Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate a...
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedic...
Femasys announces upfront investment of $6.85M by PharmaCyte
Femasys (FEMY) announced a strategic upfront investment of $6.85 million by public biotech company, PharmaCyte Biotech (PMCB) and other healthcare investors. “We are thrilled to announce this strategi...
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in de...
PharmaCyte Biotech Announces Final Results of Tender Offer
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces the final results of its previously announced tender offer to acquire up to 7,750,00...
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicab...
PharmaCyte Biotech announces second $10M share repurchase plan
PharmaCyte Biotech announced that its board of directors has authorized a second share repurchase program to repurchase up to $10M of PharmaCyte’s outstanding common stock. This second share repurchas...
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Ce...
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box® Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box®
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.
PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...
Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.
Reiterates its Belief that the Root Cause of the Company's Problems is an Insular and Dysfunctional Board Comprised of Chairman and CEO Kenneth Waggoner's Entrenched Management Team and Unqualified, H...
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
LAS VEGAS--(BUSINESS WIRE)--Preliminary Financial Results for Fiscal Year 2022 are announced by PharmaCyte Biotech, Inc.
IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS
NEW YORK , July 11, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022, that it had delivered a written consent to...